Literature DB >> 20508382

High-normal thyroid function and risk of recurrence of atrial fibrillation after catheter ablation.

Ri-Bo Tang1, Dong-Ling Liu, Jian-Zeng Dong, Xing-Peng Liu, De-Yong Long, Rong-Hui Yu, Fu-Li Hu, Jia-Hui Wu, Xiao-Hui Liu, Chang-Sheng Ma.   

Abstract

BACKGROUND: It has been shown that the concentration of serum free thyroxine (FT(4)) is independently associated with atrial fibrillation (AF), even in euthyroid persons. This study investigated the effect of a high-normal level of FT(4) on recurrence after catheter ablation of AF. METHODS AND
RESULTS: The 244 consecutive patients with paroxysmal AF and who underwent circumferential pulmonary vein isolation (PVI) were prospectively enrolled. Exclusion criteria included prior or current thyroid dysfunction on admission, amiodarone medication for 3 months before admission. After a mean follow-up of 416+/-204 (91-856) days, the recurrence rates were 14.8%, 23.0%, 33.3%, 38.7% from the lowest FT(4) quartile to the highest FT(4) quartile, respectively (P=0.016). After adjustment for age, sex, left atrial diameter, and PVI, there was an increased risk of recurrence in the subjects with the highest FT(4) quartile compared with those with the lowest quartile (hazard ratio 3.31, 95% confidence interval 1.45-7.54, P=0.004). As a continuous variable, FT(4) was also an independent predictor of recurrence (hazard ratio 1.10, 95% confidence interval 1.02-1.18, P=0.016).
CONCLUSIONS: Patients with high-normal thyroid function were at an increased risk of AF recurrence after catheter ablation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508382     DOI: 10.1253/circj.cj-09-0708

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Prevalence of right atrial non-pulmonary vein triggers in atrial fibrillation patients treated with thyroid hormone replacement therapy.

Authors:  Ki-Hun Kim; Sanghamitra Mohanty; Prasant Mohanty; Chintan Trivedi; Eli Hamilton Morris; Pasquale Santangeli; Rong Bai; Amin Al-Ahmad; John David Burkhardt; Joseph G Gallinghouse; Rodney Horton; Javier E Sanchez; Shane Bailey; Patrick M Hranitzky; Jason Zagrodzky; Soo G Kim; Luigi Di Biase; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2017-03-07       Impact factor: 1.900

2.  Blood lipid levels and recurrence of atrial fibrillation after radiofrequency catheter ablation: a prospective study.

Authors:  Yunpeng Shang; Nan Chen; Qiqi Wang; Chengui Zhuo; Jianqiang Zhao; Ning Lv; Yuan Huang
Journal:  J Interv Card Electrophysiol       Date:  2019-04-07       Impact factor: 1.900

3.  U-shaped association between serum free triiodothyronine and recurrence of atrial fibrillation after catheter ablation.

Authors:  Shao-Bin Wei; Wei Wang; Nian Liu; Ji Chen; Xue-Yuan Guo; Ri-Bo Tang; Rong-Hui Yu; De-Yong Long; Cai-Hua Sang; Chen-Xi Jiang; Song-Nan Li; Song-Nan Wen; Jia-Hui Wu; Rong Bai; Xin Du; Jian-Zeng Dong; Chang-Sheng Ma
Journal:  J Interv Card Electrophysiol       Date:  2018-02-26       Impact factor: 1.900

Review 4.  Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism.

Authors:  Narcis Tribulova; Lin Hai Kurahara; Peter Hlivak; Katsuya Hirano; Barbara Szeiffova Bacova
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

5.  The Association Between Subclinical Thyroid Dysfunction and Recurrence of Atrial Fibrillation After Catheter Ablation.

Authors:  Rui-Bin Li; Xiao-Hong Yang; Ji-Dong Zhang; Dong Wang; Xiao-Ran Cui; Long Bai; Lei Zhao; Wei Cui
Journal:  Front Cardiovasc Med       Date:  2022-06-03

6.  Higher FT4 level within the normal range predicts the outcome of cryoballoon ablation in paroxysmal atrial fibrillation patients without structural heart disease.

Authors:  Yan Pei; Shaojie Xu; Haotian Yang; Zhongyuan Ren; Weilun Meng; Yixing Zheng; Rong Guo; Shuang Li; Dongdong Zhao; Kai Tang; Hailing Li; Yawei Xu
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-07-11       Impact factor: 1.468

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.